| Dec'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-56,793 | -53,171 | -18,485 | -21,547 | - | - | - | - | - | - |
Net loss | |||||||||
- | - | - | - | 6,347 | -13,355 | -11,900 | -24,835 | -8,628 | 8,753 |
Adjustments to reconcile net loss to cash flows used in operating activities: | |||||||||
Impairment of intangible assets | |||||||||
- | - | - | - | - | - | - | 14,830 | - | - |
Amortization of intangible assets | |||||||||
2,460 | 981 | 724 | 756 | 770 | 778 | 769 | 2,037 | 3,302 | 3,289 |
Depreciation of property and equipment | |||||||||
144 | 167 | 91 | 152 | 112 | 139 | 225 | 190 | 53 | 37 |
Amortization of debt discount | |||||||||
596 | 209 | - | 0 | - | - | - | - | - | - |
Change in fair value of derivatives | |||||||||
- | - | - | - | - | - | - | 170 | 1,140 | -339 |
Amortization of bond (discount) premium on marketable securities | |||||||||
- | - | -9 | 87 | 98 | 45 | 152 | 264 | 189 | 1 |
Non-cash interest expense | |||||||||
1,052 | - | - | - | - | - | - | - | - | - |
Loss on extinguishment of debt | |||||||||
-3,810 | - | - | - | - | - | - | - | - | - |
Amortization of noncurrent portion of deferred revenue | |||||||||
- | - | 5,585 | 0 | - | - | - | - | - | - |
Amortization of noncurrent portion of deferred revenue | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Stock-based compensation | |||||||||
4,568 | 2,704 | 2,456 | 2,163 | 1,961 | 1,411 | 1,317 | 1,411 | 2,052 | 1,495 |
Change in fair value of derivative liability | |||||||||
- | -26,278 | - | 0 | - | - | - | - | - | - |
Gain on sale of property and equipment | |||||||||
- | - | - | - | - | 78 | 0 | - | - | - |
Deferred income tax benefit | |||||||||
- | - | - | - | - | - | - | -13 | - | - |
Deferred income tax benefit | |||||||||
- | - | - | - | - | - | - | - | -209 | - |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable and other current assets | |||||||||
15,304 | 167 | -120 | - | - | - | - | - | - | - |
Accounts and other receivables | |||||||||
- | - | - | -116 | 124 | -103 | -364 | 128 | -285 | 290 |
Prepaid expenses and other current assets | |||||||||
- | - | - | -187 | 136 | -1,110 | 1,272 | 44 | - | - |
Inventory | |||||||||
1,859 | - | - | 0 | - | - | - | - | - | - |
Accounts payable and accrued expenses | |||||||||
4,596 | 1,162 | 304 | - | - | - | - | - | - | - |
Right-of-use assets and operating lease liabilities | |||||||||
46 | - | - | - | - | - | - | - | - | - |
Prepaid expenses and other current assets | |||||||||
- | - | - | - | - | - | - | - | 36 | -52 |
Accounts payable | |||||||||
- | - | - | 626 | 292 | -213 | 277 | 64 | -64 | 110 |
Accrued expenses | |||||||||
- | - | - | 1,036 | 1,053 | -381 | 1,288 | -712 | 146 | - |
Deferred revenue | |||||||||
-15 | -50 | -97 | 103 | - | - | - | - | - | - |
Accrued expenses | |||||||||
- | - | - | - | - | - | - | - | - | -360 |
Deferred revenue | |||||||||
- | - | - | - | -94 | -267 | 35 | -1,895 | 880 | -3,527 |
Deferred rent | |||||||||
- | -20 | -9 | 5 | 18 | 37 | 0 | - | - | - |
Net cash used in operating activities | |||||||||
- | - | - | - | 10,297 | -10,671 | -8,745 | -9,001 | - | - |
Net cash used in operating activities | |||||||||
-56,699 | -21,907 | -20,490 | -16,316 | - | - | - | - | -3,170 | 9,899 |
Cash flows from investing activities: | |||||||||
Purchases of marketable securities | |||||||||
- | - | 5,052 | 17,517 | 10,222 | - | - | - | - | - |
Purchases of marketable securities | |||||||||
- | - | - | - | - | 2,964 | 7,758 | 15,392 | 15,963 | 2,054 |
Maturities of marketable securities | |||||||||
- | - | - | - | - | 3,350 | 14,184 | 15,299 | - | - |
Proceeds from sales of marketable securities | |||||||||
- | - | - | - | - | - | - | 1,104 | - | - |
Maturities of marketable securities | |||||||||
- | - | 18,743 | 13,168 | 3,650 | - | - | - | 6,598 | - |
Acquisition of Icon Bioscience Inc., net of cash acquired | |||||||||
- | 16,780 | - | 0 | - | - | - | - | - | - |
Purchases of property and equipment | |||||||||
213 | 108 | 147 | 113 | 161 | 248 | 68 | 405 | 133 | 15 |
Proceeds from sale of property and equipment | |||||||||
- | - | 33 | 0 | 0 | 78 | 0 | - | - | - |
Change in restricted cash | |||||||||
- | - | - | - | - | 150 | 0 | - | - | - |
Net cash (used in) provided by investing activities | |||||||||
- | - | - | - | -6,733 | 66 | 6,358 | 606 | - | - |
Net cash used in investing activities | |||||||||
-213 | -16,888 | 13,577 | -4,462 | - | - | - | - | -9,498 | -2,069 |
Cash flows from financing activities: | |||||||||
Proceeds from exercise of warrants | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Proceeds from issuance of stock, net of issuance costs | |||||||||
22,627 | 41,515 | 8,404 | 16,500 | 0 | 18,057 | - | - | 10,043 | - |
Proceeds from issuance of long-term debt | |||||||||
50,000 | 20,000 | - | 0 | - | - | - | - | - | - |
Payment of debt issue costs | |||||||||
1,341 | 1,347 | - | 0 | - | - | - | - | - | - |
Payment of long-term debt principal | |||||||||
20,000 | - | - | - | - | - | - | - | - | - |
Payment of extinguishment of debt costs | |||||||||
2,716 | - | - | - | - | - | - | - | - | - |
Net settlement of stock units to satisfy statutory tax withholding | |||||||||
120 | - | - | 0 | - | - | - | - | - | - |
Proceeds from issuance of stock, net of issuance costs | |||||||||
- | - | - | - | - | - | 4,669 | - | - | - |
Proceeds from exercise of stock options | |||||||||
414 | 503 | 99 | 490 | 235 | 987 | 0 | 114 | 17 | - |
Payment of contingent development milestone | |||||||||
15,000 | - | - | - | - | - | - | - | - | - |
Net cash provided by financing activities | |||||||||
- | - | - | - | 235 | 19,044 | 4,669 | 114 | - | - |
Proceeds from exercise of stock options and warrants | |||||||||
- | - | - | - | - | - | - | - | - | 802 |
Net cash provided by financing activities | |||||||||
33,864 | 60,671 | 8,503 | 16,990 | - | - | - | - | 10,060 | 802 |
Effect of foreign exchange rate changes on cash and cash equivalents | |||||||||
1 | 2 | -5 | -20 | - | - | - | - | - | - |
Net increase (decrease) in cash, cash equivalents and restricted cash | |||||||||
-23,047 | 21,878 | 1,585 | -3,808 | - | - | - | - | - | - |
Effect of foreign exchange rate changes on cash and cash equivalents | |||||||||
- | - | - | - | -12 | -4 | -8 | -6 | 6 | -17 |
Net decrease in cash and cash equivalents | |||||||||
- | - | - | - | 3,787 | 8,435 | 2,274 | -8,287 | -2,602 | 8,615 |
Supplemental cash flow information: | |||||||||
Cash interest paid | |||||||||
4,870 | 258 | - | 0 | - | - | - | - | - | - |
Cash paid for income taxes | |||||||||
- | - | - | - | 263 | 0 | 0 | - | 56 | 266 |
Supplemental disclosure of non-cash investing and financing activities: | |||||||||
Accrued development milestone | |||||||||
- | 15,000 | - | 0 | - | - | - | - | - | - |
Accrued term loan exit fee | |||||||||
3,000 | 1,200 | - | - | - | - | - | - | - | - |
Fair value of second tranche purchase liability | |||||||||
- | 4,734 | - | 0 | - | - | - | - | - | - |
Fair value of warrants issued with debt | |||||||||
- | 355 | - | 0 | - | - | - | - | - | - |
Fair value of second tranche warrants | |||||||||
- | 18,165 | - | 0 | - | - | - | - | - | - |